EyePoint Pharmaceuticals, Inc.
20
3
5
11
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
20.0%
4 terminated/withdrawn out of 20 trials
73.3%
-13.2% vs industry average
60%
12 trials in Phase 3/4
91%
10 of 11 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (20)
COMO: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME
Role: lead
CAPRI: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME
Role: lead
A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUCIA) Primary Efficacy Will be Determined at Week 56
Role: lead
A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUGANO) Primary Efficacy Will be Determined at Week 56
Role: lead
Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD)
Role: lead
Study of EYP-1901 in Patients With Nonproliferative Diabetic Retinopathy (NPDR)
Role: lead
A Study to Evaluate the Efficacy and Safety of DEXYCU® for the Treatment of Ocular Pain Associated With Cataract Surgery
Role: lead
Evaluate the Safety of DEXYCU for the Treatment of Inflammation Following Ocular Surgery for Childhood Cataract
Role: lead
Study of EYP-1901 in Patients With Diabetic Macular Edema (DME)
Role: lead
"A Prospective Study of the Efficacy of Intracameral Dexamethasone (Dexycu™) Compared to Standard of Care Treatment for Post-Cataract Surgical Pain and Anterior Chamber Inflammation"
Role: collaborator
Safety and Efficacy of an Injectable Fluocinolone Acetonide Intravitreal (FAI) Insert
Role: lead
A Study to Evaluate the Efficacy and Safety of DEXYCU® for the Treatment of Ocular Pain Associated With Cataract Surgery (2)
Role: lead
First in Human Study to Evaluate the Safety and Tolerability of EYP-1901 in Patients With Wet Age Related Macular Degeneration (wAMD)
Role: lead
The TIME-2b Study: A Study of AKB-9778 (Razuprotafib), a Novel Tie 2 Activator, in Patients With Non-Proliferative Diabetic Retinopathy (NPDR)
Role: lead
Evaluation of the Safety and Efficacy of Razuprotafib in Hospitalized Subjects With Coronavirus Disease 2019
Role: lead
Study to Assess the Efficacy, Safety and Tolerability of AKB-9778 Ophthalmic Solution as and Adjunct to Latanoprost in Patients With Ocular Hypertension or Open Angle Glaucoma
Role: lead
DEXYCU (Dexamethasone Intraocular Suspension) 9% Retrospective Study 001
Role: lead
Safety and Efficacy of an Injectable Fluocinolone Acetonide Intravitreal Insert
Role: lead
Safety and Efficacy Study of a FAI Insert in Subjects With Chronic Non-infectious Posterior Uveitis
Role: lead
Utilization and Safety of the Mk II Inserter and the Safety of the FAI Insert in Non-Infectious Uveitis
Role: lead
All 20 trials loaded